Godavari Drugs Limited Fundamental Analysis (BSE: GODAVARI.BO)
Godavari Drugs Limited Fundamental Analysis (BSE: GODAVARI.BO)
Godavari Drugs Limited (BSE: GODAVARI.BO) shows weak financial fundamentals with a PE ratio of 18.83, profit margin of 3.78%, and ROE of 7.92%. The company generates $1.1B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 34.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze GODAVARI.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakGODAVARI.BO struggles to generate sufficient returns from assets.
Valuation Score
ModerateGODAVARI.BO shows balanced valuation metrics.
Growth Score
ModerateGODAVARI.BO shows steady but slowing expansion.
Financial Health Score
ModerateGODAVARI.BO shows balanced financial health with some risks.
Profitability Score
WeakGODAVARI.BO struggles to sustain strong margins.
Key Financial Metrics
Is GODAVARI.BO Expensive or Cheap?
P/E Ratio
GODAVARI.BO trades at 18.83 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, GODAVARI.BO's PEG of 8.63 indicates potential overvaluation.
Price to Book
The market values Godavari Drugs Limited at 1.30 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 3.44 times EBITDA. This is generally considered low.
How Well Does GODAVARI.BO Make Money?
Net Profit Margin
For every $100 in sales, Godavari Drugs Limited keeps $3.78 as profit after all expenses.
Operating Margin
Core operations generate 6.83 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $7.92 in profit for every $100 of shareholder equity.
ROA
Godavari Drugs Limited generates $2.07 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Godavari Drugs Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Godavari Drugs Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
GODAVARI.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
18.83
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
8.63
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.30
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.89
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.007
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.31
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.08
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.07
vs 25 benchmark
How GODAVARI.BO Stacks Against Its Sector Peers
| Metric | GODAVARI.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 18.83 | 32.02 | Better (Cheaper) |
| ROE | 7.92% | 569.00% | Weak |
| Net Margin | 3.78% | 29948.00% | Weak |
| Debt/Equity | 1.01 | 0.53 | Weak (High Leverage) |
| Current Ratio | 1.31 | 5.67 | Neutral |
| ROA | 2.07% | -98.00% (disorted) | Weak |
GODAVARI.BO outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Godavari Drugs Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation